Chapter I General Provisions

Article 1 This board diversity policy (hereinafter referred to as the “Policy”) is formulated in accordance with the relevant laws and regulations such as the Company Law of the People’s Republic of China and the Articles of Association of Joincare Pharmaceutical Group Industry Co., Ltd. for the purpose of diversifying the members of the Board of Directors of Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as the “Company” or “we”, “our”).

Chapter II General Policy

Article 2 The Company recognizes the importance of board diversity for realizing effective corporate governance and board performance.

Article 3 In order to achieve sustainable and balanced development, the Company regards the increasing diversity at the board level as a key element to support our strategic goals and maintain sustainable development. All appointments to the Board of Directors are based on meritocracy, and the benefits of board diversity shall be fully taken into account with appropriate criteria in the selection of candidates.

Article 4 The Company is committed to selecting the best candidates for members of the Board of Directors. Candidates will be selected based on a range of diversity aspects, including but not limited to educational background, professional experience, skill, knowledge and service tenure, as well as gender, age, nationality, cultural background and ethnicity or race. The final decision will be based on the strengths and potential contributions of the candidates to the Board of Directors.

Article 5 The nomination committee of the Board of Directors of the Company (hereinafter referred to as the “Nomination Committee”) is mainly responsible for identifying persons with suitable qualifications to serve as directors, and fully considering the board diversity policy in the selection process, monitoring the implementation of the Policy, and reviewing and revising the Policy as appropriate to ensure its effectiveness. All appointments to the Board of Directors will fully consider the benefits of board diversity and the merits of each candidate and be determined based on objective criteria.

Chapter III Supervision and Reporting

Article 6 The Nomination Committee will review the Policy as appropriate to ensure its effectiveness. The Nomination Committee will discuss amendments to the Policy when necessary.

Chapter IV Disclosure of the Policy

Article 7 The Policy will be published on the Company’s website for the purpose of disclosing the relevant information to the public. A summary of the Policy and any measurable objectives and progress towards achieving them which are established for implementing the Policy will be disclosed annually in the social responsibility report.

Chapter V Supplementary Provisions

Article 8 The Company pays close attention to the relevant policies on and the development trends of board diversity at home and abroad and examines and improves the Policy from time to time for the purpose of enhancing the effectiveness of sustainable development. If the Policy conflicts with the laws, administrative regulations or normative documents promulgated by the state in the future or the Articles of Association of the Company amended through legal procedures, it shall be implemented in accordance with the relevant laws, administrative regulations, normative documents or the Articles of Association of the Company, and the Policy shall be revised if necessary.

Joincare Pharmaceutical Group Industry Co., Ltd.

7 April 2023